MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Clinical trials for MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough T-Cell lymphoma
Disease control TerminatedThis early-phase trial tests whether combining two existing drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. T…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:39 UTC
-
New combo therapy holds promise for Tough-to-Treat lymphoma
Disease control TerminatedThis study is for people with a rare and aggressive type of lymphoma (peripheral T-cell lymphoma) that hasn't been treated yet. It compares standard chemotherapy alone to chemotherapy plus either duvelisib or CC-486, two drugs that may help stop cancer growth. The goal is to see …
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 04:37 UTC
-
Promising lymphoma combo study pulled before starting
Disease control TerminatedThis study was designed to see if adding tazemetostat to standard CHOP chemotherapy could improve outcomes for people with untreated peripheral T cell lymphoma. It was withdrawn before any participants enrolled, so no results are available. The goal was to increase the number of …
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new treatment called WU-CART-007 for people with certain blood cancers (like acute myeloid leukemia and T-cell lymphoma) that have not responded to standard therapy. The treatment uses donor immune cells that are specially modified to target and kil…
Matched conditions: MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC